{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:34:53Z","timestamp":1767144893779,"version":"build-2238731810"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clgc.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T01:58:50Z","timestamp":1569549530000},"page":"69-76.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-2531","authenticated-orcid":false,"given":"Orazio","family":"Caffo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Wissing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diletta","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik B.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Bournakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avishay","family":"Sella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.09.010_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.09.010_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.010_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.010_bib4","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.urology.2011.11.043","article-title":"Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors","volume":"79","author":"Caffo","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2019.09.010_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bju.12845","article-title":"Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer","volume":"115","author":"Oudard","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.09.010_bib7","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ejca.2013.09.026","article-title":"Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer","volume":"49","author":"van Soest","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib9","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib10","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.240","article-title":"Enzalutamide after abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"32","author":"Sandhu","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.247","article-title":"Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone","volume":"32","author":"Scholz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.125","article-title":"The sequential use of abiraterone and enzalutamide in metastatic castration resistant prostate cancer patients: experience from seven U.K. centers","volume":"32","author":"Stevenson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejca.2013.12.017","article-title":"Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer","volume":"50","author":"Thomson","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.159","article-title":"Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience","volume":"32","author":"Vera-Badillo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.eururo.2013.11.044","article-title":"Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents","volume":"66","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib18","article-title":"Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)","volume":"49","author":"Sonpavde","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clgc.2015.01.004","article-title":"Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)33512-2","article-title":"Response to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate","volume":"23","author":"Albiges","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cncr.28518","article-title":"Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment","volume":"120","author":"Badrising","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib23","article-title":"Enzalutamide (ENZA) in heavily pretreated patients with bone metastatic castration resistant prostate cancer (mCRPC) resistant to androgen biosynthesis inhibitor (ABI) treatment - the Hellenic experience of the Name Patient Access Program (NPAP)","volume":"49","author":"Bournakis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study","volume":"68","author":"Caffo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.18","article-title":"The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC","volume":"32","author":"Cheng","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12325-014-0092-1","article-title":"Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer","volume":"31","author":"Schmid","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2019.09.010_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/21681805.2013.860189","article-title":"Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate","volume":"48","author":"Thomsen","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clgc.2014.06.007","article-title":"Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer","volume":"12","author":"Sella","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib29","doi-asserted-by":"crossref","first-page":"E760","DOI":"10.1002\/ijc.29231","article-title":"CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel","volume":"136","author":"Wissing","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies","volume":"68","author":"Al Nakouzi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.010_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(16)31360-0","article-title":"Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.010_bib32","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clgc.2019.09.010_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clgc.2019.09.010_bib34","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2019.09.010_bib35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.critrevonc.2015.07.013","article-title":"Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"96","author":"Maines","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2019.09.010_bib36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.010_bib37","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib38","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.010_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2019.09.010_bib40","doi-asserted-by":"crossref","unstructured":"Oh WK, Miao R, Vekeman F, et al. Real-world characteristics and outcomes of patients with metastatic castration-resistant prostate cancer receiving chemotherapy versus androgen receptor-targeted therapy after failure of first-line androgen receptor-targeted therapy in the community setting [e-pub ahead of print]. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2017.06.004.","DOI":"10.1016\/j.clgc.2017.06.004"}],"updated-by":[{"DOI":"10.1016\/j.clgc.2020.03.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000}}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:59Z","timestamp":1761564719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1558767319302794"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}